Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Clinical analysis of 670 cases in two trials of the European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group subtyped according to the Revised European-American Classification of Lymphoid Neoplasms: a comparison with the Working Formulation Pittaluga S; Bijnens L; Teodorovic I; Hagenbeek A; Meerwaldt JH; Somers R; Thomas J; Noordijk EM; De Wolf-Peeters CBlood 1996[May]; 87 (10): 4358-67In the Working Formulation (WF), non-Hodgkin's lymphomas (NHL) are grouped according to their clinical behavior. These disorders are listed as entities defined by morphology, phenotype, and cytogenetics in the proposed Revised European-American Classification of Lymphoid Neoplasms (REAL), the clinical relevance of which is still debated. We analyzed 670 NHL cases included in two randomized clinical trials (EORTC 20855 WF-intermediate/high-grade and 20856 WF-low-grade malignancy) with histologic material available for review. Based on hematoxylin-eosin-stained sections, 77% of cases could be subtyped. Immunophenotyping was considered to be mandatory only in diagnosing T-cell lymphoma and anaplastic large-cell lymphoma. Of 522 cases subtyped, 11% were mantle cell lymphoma (MCL), 5% were marginal zone B-cell lymphoma (MZBCL), 46% were follicle center lymphoma, and 32% were diffuse large B-cell lymphoma. Statistical analysis and comparisons between classifications were made only within each trial and treatment group. MCL and MZBCL were characterized by a shorter median survival (3.4 and 4.1 years, respectively) in comparison with low- and intermediate-grade WF groups (> 9.3 and 5.8 years, respectively). In terms of progression-free survival, MCL showed a behavior similar to the low-grade group, with frequent relapses. Follicle center cell lymphomas behaved as low-grade lymphomas as defined by the WF and diffuse large B-cell lymphomas as the WF-intermediate grade group. Because several NHL entities have a clinical behavior of their own, their recognition by the REAL classification offers clinicians additional information that is not obtained when the WF is used.|Antineoplastic Combined Chemotherapy Protocols/therapeutic use[MESH]|Bleomycin/administration & dosage[MESH]|Bone Marrow/pathology[MESH]|Combined Modality Therapy[MESH]|Cyclophosphamide/administration & dosage[MESH]|Disease-Free Survival[MESH]|Doxorubicin/administration & dosage[MESH]|Etoposide/administration & dosage[MESH]|Humans[MESH]|Immunologic Factors/therapeutic use[MESH]|Immunophenotyping[MESH]|Interferon alpha-2[MESH]|Interferon-alpha/therapeutic use[MESH]|Life Tables[MESH]|Lymphoma, Non-Hodgkin/*classification/mortality/pathology/therapy[MESH]|Mechlorethamine/administration & dosage[MESH]|Methotrexate/administration & dosage[MESH]|Prednisone/administration & dosage[MESH]|Procarbazine/administration & dosage[MESH]|Prognosis[MESH]|Recombinant Proteins[MESH]|Survival Analysis[MESH]|Survival Rate[MESH]|Vincristine/administration & dosage[MESH] |